Bristol Myers Squibb Announces Phase 3 ALOFT-IPF Trial Evaluating Admilparant in Adults with Idiopathic Pulmonary Fibrosis Met Primary Endpoint
Bristol Myers Squibb's pivotal Phase 3 ALOFT-IPF trial of admilparant met its primary endpoint at the 60 mg twice-daily dose, showing a statistically significant improvement in FVC change from baseline to Week 52 versus placebo. The 120 mg dose slowed FVC decline but missed statistical significance, while safety and discontinuation rates were comparable to placebo across both doses.
Key figures
- Drug Name
- admilparant (BMS-986278)
- Phase Of Trial
- Phase 3
- Doses evaluated
- ["60 mg","120 mg"]
- Primary endpoint
- absolute change in FVC from baseline to Week 52
- Trial enrollment
- 1255
- Ipf patients globally
- 1400000
- Phase2 ipf relative reduction
- 62%
- Phase2 ppf relative reduction
- 69%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.